See the DrugPatentWatch profile for Alirocumab
Alirocumab's primary patents are set to expire in 2025 and 2027, with some foundational patents expiring even earlier in 2023 [1]. These patent expiries are significant for the future availability and pricing of the drug.
When does Alirocumab exclusivity end?
While the main patents for alirocumab expire around 2025-2027, the exact end of market exclusivity can depend on various factors, including secondary patents, regulatory exclusivities, and potential legal challenges [1]. DrugPatentWatch.com tracks these dates closely.
What happens after Alirocumab patents expire?
Following patent expiry, the pathway opens for the development and potential approval of generic or biosimilar versions of alirocumab. This typically leads to increased competition and can result in lower drug prices for patients and healthcare systems [1].
Can biosimilars be approved before patent expiry?
In some cases, biosimilar manufacturers may seek approval for their products before the primary patents expire. This often involves challenging the validity or scope of existing patents through litigation. However, approval does not necessarily mean market entry if the patents are upheld [1].
Who makes Alirocumab?
Alirocumab is marketed by Sanofi and Regeneron Pharmaceuticals under the brand name Praluent [2].
How does Praluent work?
Praluent is a monoclonal antibody that inhibits the PCSK9 protein. By blocking PCSK9, it increases the number of LDL receptors on the liver, leading to lower levels of LDL cholesterol ("bad" cholesterol) in the blood [2].
What are the alternatives to Praluent?
Alternatives for managing high LDL cholesterol include statins, ezetimibe, and other PCSK9 inhibitors like evolocumab. Lifestyle modifications, such as diet and exercise, are also crucial [2].
What is the cost of Praluent?
The cost of Praluent can vary significantly based on insurance coverage, geographic location, and dosage. Historically, PCSK9 inhibitors have been associated with high price tags, which is a key reason why patent expiry and the advent of generics are anticipated [2].
What are the side effects of Praluent?
Common side effects of alirocumab can include reactions at the injection site, flu-like symptoms, and upper respiratory tract infections. Less common but more serious side effects have also been reported [2].
What is the clinical data for Alirocumab?
Clinical trials, such as the ODYSSEY program, have demonstrated alirocumab's efficacy in significantly lowering LDL cholesterol levels in various patient populations, including those with familial hypercholesterolemia and high cardiovascular risk [2].
Sources:
1. DrugPatentWatch.com
2. Praluent Prescribing Information